Corporate

pen

Vastrata’s strategies and operations are focused on developing a more efficient way to discover and select new drugs for development through leveraging the huge database of existing clinical data. This strategic analysis and novel discovery paradigm enables:

  • a reduced attrition rate between target identification and a positive demonstration of an in vivo result (in either animal models or humans) with a candidate compound;
  • shortened development timelines and lower costs for development, thereby accelerating time to market ;

The Company seeks and utilizes clinical data as early as possible to identify commercial opportunities. This is facilitated by concentrating on agents that have already been used in some form in man as the starting point for the therapeutic programme. This allows established, peer reviewed data on their efficacy and side effect profiles to be analysed and compared to their pharmacological and pharmacokinetic properties to identify areas for clinical refinement and improvement.

In defining its own programmes, the Company scores candidates using the following criteria:

  1. Development tractability;
  2. Ease of Proof-of-Concept studies;
  3. Length of preclinical and/or clinical trial(s);
  4. Cost of preclinical and/or clinical trial(s);
  5. Inherent chances of success;
  6. Clinical support;
  7. Market opportunity;
  8. Key value inflection points identified for partnering/out-licensing;
  9. Thorough assessment of surrounding Intellectual Property and Freedom to Operate issues.

At a broader level, the Company’s three main strategies for drug discovery involves:

  1. Identification of reprofiling/repurposing therapeutics – protected by patents for new therapeutic use applications and enhanced where possible with new formulation patents using novel bespoke technologies of identified partners;
  2. Identification of New Chemical Entities (NCEs) – protected by substance of matter patents and new medical use patents;
  3. Pharmacodynamic and pharmacokinetic evaluation of modifications of established drugs with known efficacy and known limitations – protected by patent strategy outlined above.

Driving Vastrata’s approach is a focus on patient needs (rather than focusing merely on surrogate endpoints) and on delivering novel medicines in key therapeutic areas.

This is achieved by using astute clinical observation as the starting point and combining this with chemical optimization of a drug with already established ADMET. The approach enables a coupling of classic ‘black box’, whole organism, screening, in the most clinically useful organism of all – man – with intelligent chemistry.